Detail publikace

Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas

KEUNEN, O. TAXT, T. BARTOŠ, M. JIŘÍK, R. THORSEN, F. JOHANSSON, M. OUDIN, A. SANZEY, M. ABDULRAHIM, S. FACK, F. BJERKVIG, R. NICLOU, S.

Originální název

Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas

Anglický název

Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas

Typ

abstrakt

Jazyk

čeština

Originální abstrakt

Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults. Despite important progress in the molecular characterization of GBMs in recent years, treatment efficacy has only improved marginally and median survival after diagnosis is still limited to about 14 months. GBMs are highly vascularised tumors and endothelial cell proliferation is one of the neuropathological hallmarks of the disease. Therefore the concept of interfering with blood vessel formation has long been proposed as a promising strategy against GBM. Recent clinical trials have shown good radiological response rates with bevacizumab, an antibody against vascular endothelial growth factor (VEGF). Yet, it is currently not known through which biological mechanisms bevacizumab exerts its effect, and whether it has a true anti-tumor effect.

Anglický abstrakt

Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults. Despite important progress in the molecular characterization of GBMs in recent years, treatment efficacy has only improved marginally and median survival after diagnosis is still limited to about 14 months. GBMs are highly vascularised tumors and endothelial cell proliferation is one of the neuropathological hallmarks of the disease. Therefore the concept of interfering with blood vessel formation has long been proposed as a promising strategy against GBM. Recent clinical trials have shown good radiological response rates with bevacizumab, an antibody against vascular endothelial growth factor (VEGF). Yet, it is currently not known through which biological mechanisms bevacizumab exerts its effect, and whether it has a true anti-tumor effect.

Klíčová slova

GBM, VEGF, DCE-MRI, DWI, MRS

Klíčová slova v angličtině

GBM, VEGF, DCE-MRI, DWI, MRS

Autoři

KEUNEN, O.; TAXT, T.; BARTOŠ, M.; JIŘÍK, R.; THORSEN, F.; JOHANSSON, M.; OUDIN, A.; SANZEY, M.; ABDULRAHIM, S.; FACK, F.; BJERKVIG, R.; NICLOU, S.

Vydáno

5. 11. 2010

Strany od

3

Strany do

4

Strany počet

2

URL

http://lucilinx.lu/symposium2010.php

BibTex

@misc{BUT61024,
  author="Olivier {Keunen} and Torfinn {Taxt} and Michal {Bartoš} and Radovan {Jiřík} and Frits {Thorsen} and Mikael {Johansson} and Anais {Oudin} and Morgane {Sanzey} and Siti Aminah {Abdulrahim} and Fred {Fack} and Rolf {Bjerkvig} and Simone {Niclou}",
  title="Multi-modal imaging and pharmacokinetic modeling shed light on mechanism of action of anti-angiogenic therapy in malignant gliomas",
  booktitle="Methods and Applications in Bioinformatics: From ideas to results",
  year="2010",
  pages="3--4",
  url="http://lucilinx.lu/symposium2010.php",
  note="abstract"
}